Amlitelimab

Amlitelimab () is an anti-OX40 Ligand (OX40L) monoclonal antibody (mAb) . Amlitelimab inhibits OX40-OX40L interaction, and can be used in the research of atopic dermatitis[1][2][3].

Product Specifications

CAS Number

[2378692-15-8]

Product Name Alternative

KY1005; SAR445229

UNSPSC

12352203

Target

Others

Type

Inhibitory Antibodies

Related Pathways

Others

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/amlitelimab.html

Purity

98.23

Solubility

10 mM in DMSO

Smiles

[Amlitelimab]

Molecular Weight

(145.94 kDa)

References & Citations

[1]Ana Maria Lé, et al. OX40-OX40L Inhibition for the Treatment of Atopic Dermatitis-Focus on Rocatinlimab and Amlitelimab. Pharmaceutics 2022, 14 (12), 2753. |[2]Saghari M, et al. OX40L Inhibition Suppresses KLH-driven Immune Responses in Healthy Volunteers: A Randomized Controlled Trial Demonstrating Proof-of-Pharmacology for KY1005. Clin Pharmacol Ther. 2022 May;111 (5) :1121-1132. |[3]Tkachev V, et al. Combined OX40L and mTOR blockade controls effector T cell activation while preserving Treg reconstitution after transplant. Sci Transl Med. 2017 Sep 20;9 (408) :eaan3085.